Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

highstress plastics ltd - copper naphthenate - mixed function pesticide - timber | wood - borer | fungal decay | decay fungi

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

highstress plastics ltd - copper naphthenate - mixed function pesticide - timber | wood - fungal decay | insect pest of timber | borers | decay fungi | lyctids | quarantine timber insects | termite | timber destroying insects

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - ? hypoxia of any cause. ? as diluent for gaseous and volatile anaesthetic agents.

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - angelica sinensis root (unii: b66f4574ug) (angelica sinensis root - unii:b66f4574ug), american ginseng (unii: 8w75vcv53q) (american ginseng - unii:8w75vcv53q), silver nitrate (unii: 95it3w8jze) (silver cation - unii:57n7b0k90a), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), capsicum (unii: 00uk7646fg) (capsicum - unii:00uk7646fg), cinchona officinalis bark (unii: s003a158sb) (cinchona officinalis bark - unii:s003a158sb), digitalis (unii: f1t8qt9u8b) (digitalis - unii:f1 - distress - mood - sadness formulated for associated symptoms such as irritability, grief, despondency, difficult concentration, oversensitivity and prolonged sadness. formulated for associated symptoms such as irritability, grief, despondency, difficult concentration, oversensitivity and prolonged sadness.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - solution for injection - trastuzumab 600 mg / 5 ml - trastuzumab - breast cancermetastatic breast cancerherceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. - in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive mbc, not previously treated with trastuzumab.early breast cancerherceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). - following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) . - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. - in combination with neoadjuvant chemotherapy followed by adjuvant herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameterherceptin should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay .

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - avena sativa 1x asafoetida 3x corydalis canadensis 3x hyoscyamus niger 3x sumbul 6x valeriana officinalis 3x cicuta virosa 4x ignatia amara 4x olei gaultheria procumbens 4x staphysagria 4x - for the temporary relief of feeling distressed or a tendency towards overreaction.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Malta - English - Medicines Authority

tilman sa zi sud 15, baillonville, 5377, , belgium - film-coated tablet - passiflora incarnata 500 mg - psycholeptics

Israel - English - Ministry of Health

sanofi israel ltd - alglucosidase alfa - powder for concentrate for infusion - alglucosidase alfa 50 mg/vial - alglucosidase alfa - alglucosidase alfa - myozyme is indicated for long-term enzyme replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). the benefits of myozyme in patients with late-onset pompe disease have not been established.

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - trastuzumab - injection, powder, for solution - 440 mg/vial - trastuzumab 440 mg/vial